Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 24451687)

1.

Therapeutic effects of serelaxin in acute heart failure.

Du XJ, Hewitson TD, Nguyen MN, Samuel CS.

Circ J. 2014;78(3):542-52. Epub 2014 Jan 23.

2.

Serelaxin : a potential new drug for the treatment of acute heart failure.

Neverova N, Teerlink JR.

Expert Opin Investig Drugs. 2014 Jul;23(7):1017-26. doi: 10.1517/13543784.2014.924504. Epub 2014 May 28. Review.

PMID:
24865798
3.

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators.

Lancet. 2013 Jan 5;381(9860):29-39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7.

PMID:
23141816
4.

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.

Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR; RELAX-AHF Investigators.

J Am Coll Cardiol. 2013 Jan 15;61(2):196-206. doi: 10.1016/j.jacc.2012.11.005.

5.

Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.

Felker GM, Teerlink JR, Butler J, Hernandez AF, Miller AB, Cotter G, Davison BA, Filippatos G, Greenberg BH, Ponikowski P, Voors AA, Hua TA, Severin TM, Unemori E, Metra M.

J Am Coll Cardiol. 2014 Oct 14;64(15):1591-8. doi: 10.1016/j.jacc.2014.05.071.

PMID:
25301463
6.

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.

Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua T, Ponikowski P, Severin T, Unemori E, Voors AA, Metra M.

Eur Heart J. 2014 Apr;35(16):1041-50. doi: 10.1093/eurheartj/eht497. Epub 2013 Dec 6.

7.

Emerging role of serelaxin in the therapeutic armamentarium for heart failure.

Varr BC, Maurer MS.

Curr Atheroscler Rep. 2014 Oct;16(10):447. doi: 10.1007/s11883-014-0447-8. Review.

PMID:
25108571
8.

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.

Metra M, Ponikowski P, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Hua TA, Severin T, Unemori E, Voors AA, Teerlink JR.

Eur Heart J. 2013 Oct;34(40):3128-36. doi: 10.1093/eurheartj/eht371. Epub 2013 Sep 2.

9.

Serelaxin: new investigational treatment in acute heart failure.

Said S, Mukherjee D.

Cardiovasc Hematol Agents Med Chem. 2013 Sep;11(3):243-8. Review.

PMID:
24289727
10.

Serelaxin a novel treatment for acute heart failure.

Castrini AI, Carubelli V, Lazzarini V, Bonadei I, Lombardi C, Metra M.

Expert Rev Clin Pharmacol. 2015 Sep;8(5):549-57. doi: 10.1586/17512433.2015.1073587.

PMID:
26294074
11.

Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond.

Cotter G, Milo O, Davison BA.

Curr Heart Fail Rep. 2014 Mar;11(1):19-30. doi: 10.1007/s11897-013-0180-6. Review.

PMID:
24363020
12.

Representativeness of RELAX-AHF clinical trial population in acute heart failure.

Wang TS, Hellkamp AS, Patel CB, Ezekowitz JA, Fonarow GC, Hernandez AF.

Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):259-68. doi: 10.1161/CIRCOUTCOMES.113.000418. Epub 2014 Mar 4.

13.

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.

Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, Cotter G, Milo O, Laessing U, Zhang Y, Dahlke M, Zymlinski R, Metra M.

Eur Heart J. 2014 Feb;35(7):431-41. doi: 10.1093/eurheartj/eht459. Epub 2013 Nov 18.

14.

Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure?

Dschietzig TB.

Am J Cardiovasc Drugs. 2014 Oct;14(5):343-55. doi: 10.1007/s40256-014-0078-z. Review.

PMID:
24934696
15.

Design of the RELAXin in acute heart failure study.

Ponikowski P, Metra M, Teerlink JR, Unemori E, Felker GM, Voors AA, Filippatos G, Greenberg B, Teichman SL, Severin T, Mueller-Velten G, Cotter G, Davison BA.

Am Heart J. 2012 Feb;163(2):149-55.e1. doi: 10.1016/j.ahj.2011.10.009.

PMID:
22305830
16.

[Organ-protection therapy. A new therapeutic approach for acute heart failure?].

Chivite D, Formiga F, Corbella X.

Med Clin (Barc). 2014 Mar;142 Suppl 1:66-71. doi: 10.1016/S0025-7753(14)70086-7. Review. Spanish.

PMID:
24930087
17.

Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012.

von Haehling S.

Expert Opin Investig Drugs. 2013 Jul;22(7):933-7. doi: 10.1517/13543784.2013.798301. Epub 2013 May 9.

PMID:
23656525
18.

Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.

Díez J.

Am J Cardiovasc Drugs. 2014 Aug;14(4):275-85. doi: 10.1007/s40256-014-0069-0.

19.

[The RELAX-AHF study].

Mortara A.

G Ital Cardiol (Rome). 2015 Apr;16(4):193-7. doi: 10.1714/1848.20174. Italian. No abstract available.

PMID:
25959752
20.

Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation.

Leo CH, Jelinic M, Parkington HC, Tare M, Parry LJ.

J Am Heart Assoc. 2014 Feb 28;3(1):e000493. doi: 10.1161/JAHA.113.000493.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk